$HURA
DELMAR PHARMACEUTICALS, INC. Stock $hura

$hura Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-K Financial Statement

#000095017022018865 Filed on September 27, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.475M	$1.454M	$7.509M
YoY Change	-32.28%	-45.46%	-23.04%
% of Gross Profit
Research & Development	$3.171M	$4.004M	$15.17M
YoY Change	-16.4%	-0.67%	-45.63%
% of Gross Profit
Depreciation & Amortization	$15.00K	$15.00K	$60.00K
YoY Change	0.0%	25.0%	100.0%
% of Gross Profit
Operating Expenses	$4.646M	$5.458M	$22.68M
YoY Change	-22.19%	-18.5%	-39.78%
Operating Profit
YoY Change
Interest Expense	$50.00K	$12.00K	$21.00K
YoY Change	900.0%	-134.29%	-30.0%
% of Operating Profit
Other Income/Expense, Net	$50.00K		$21.00K
YoY Change	900.0%		-115.91%
Pretax Income	-$4.596M	-$5.446M	-$22.66M
YoY Change	-22.96%	-19.1%	-40.83%
Income Tax
% Of Pretax Income
Net Earnings	-$4.596M	-$5.446M	-$22.66M
YoY Change	-22.96%	-19.1%	-40.83%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.07		-$0.52
Diluted Earnings Per Share	-$3.139M	-$86.47K	-$465.3K
COMMON SHARES
Basic Shares Outstanding	80.81M	65.53M	48.70M
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q3	2022 Q2	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.085M	$11.78M	$11.78M
YoY Change	-63.36%	11.8%	11.8%
Cash & Equivalents	$7.085M	$11.78M	$11.78M
Short-Term Investments
Other Short-Term Assets	$1.071M	$1.478M	$1.478M
YoY Change	39.27%	17.68%	17.68%
Inventory
Prepaid Expenses	$1.071M	$1.478M
Receivables
Other Receivables
Total Short-Term Assets	$8.156M	$13.26M	$13.26M
YoY Change	-59.44%	12.42%	12.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$754.0K	$90.00K	$90.00K
YoY Change	458.52%	-40.0%	-40.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.300M	$2.600M	$2.600M
YoY Change	104.76%	62.5%	62.5%
Total Long-Term Assets	$5.054M	$2.690M	$2.690M
YoY Change	126.13%	53.71%	53.71%
TOTAL ASSETS
Total Short-Term Assets	$8.156M	$13.26M	$13.26M
Total Long-Term Assets	$5.054M	$2.690M	$2.690M
Total Assets	$13.21M	$15.95M	$15.95M
YoY Change	-40.88%	17.76%	17.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.943M	$3.269M	$3.269M
YoY Change	17.25%	47.32%	47.32%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.516M	$3.990M	$3.990M
YoY Change	17.16%	43.53%	43.53%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$76.00K	$163.0K	$163.0K
YoY Change	-57.54%	-10.44%	-10.44%
Total Long-Term Liabilities	$76.00K	$163.0K	$163.0K
YoY Change	-57.54%	-10.44%	-10.44%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.516M	$3.990M	$3.990M
Total Long-Term Liabilities	$76.00K	$163.0K	$163.0K
Total Liabilities	$3.592M	$4.153M	$4.153M
YoY Change	12.96%	40.21%	40.21%
SHAREHOLDERS EQUITY
Retained Earnings	-$141.3M	-$136.4M
YoY Change	18.1%	22.59%
Common Stock	$138.4M	$135.6M
YoY Change	10.58%	26.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.618M	$11.80M	$11.80M
YoY Change
Total Liabilities & Shareholders Equity	$13.21M	$15.95M	$15.95M
YoY Change	-40.88%	17.76%	17.76%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022
OPERATING ACTIVITIES
Net Income	-$4.596M	-$5.446M	-$22.66M
YoY Change	-22.96%	-19.1%	-40.83%
Depreciation, Depletion And Amortization	$15.00K	$15.00K	$60.00K
YoY Change	0.0%	25.0%	100.0%
Cash From Operating Activities	-$6.369M	-$4.992M	-$20.39M
YoY Change	25.55%	6.44%	8.12%
INVESTING ACTIVITIES
Capital Expenditures	$859.0K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash From Investing Activities	-$232.0K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.906M	7.933M	21.64M
YoY Change	-86.26%	-1722.29%	-16.92%
NET CHANGE
Cash From Operating Activities	-6.369M	-4.992M	-20.39M
Cash From Investing Activities	-232.0K	0.000	0.000
Cash From Financing Activities	1.906M	7.933M	21.64M
Net Change In Cash	-4.695M	2.941M	1.243M
YoY Change	-153.34%	-156.83%	-84.74%
FREE CASH FLOW
Cash From Operating Activities	-$6.369M	-$4.992M	-$20.39M
Capital Expenditures	$859.0K	$0.00	$0.00
Free Cash Flow	-$7.228M	-$4.992M	-$20.39M
YoY Change		6.39%	8.17%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q4	dei	Entity Public Float EntityPublicFloat	24700000
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	80807316
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	11795000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	10581000
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2021	us-gaap	Open Tax Year OpenTaxYear	2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001498382
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2022	us-gaap	Open Tax Year OpenTaxYear	2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-37823
CY2022	dei	Entity Registrant Name EntityRegistrantName	Kintara Therapeutics, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	99-0360497
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	9920 Pacific Heights Blvd
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 150
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2022	dei	City Area Code CityAreaCode	858
CY2022	dei	Local Phone Number LocalPhoneNumber	350-4364
CY2022	dei	Security12b Title Security12bTitle	Common Stock
CY2022	dei	Trading Symbol TradingSymbol	KTRA
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022	dei	Auditor Firm AuditorFirmId	688
CY2022	dei	Auditor Name AuditorName	Marcum LLP
CY2022	dei	Auditor Location AuditorLocation	San Francisco, CA
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11780000
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10537000
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1478000
CY2021Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	756000
CY2021Q2	ktra	Clinical Trial Deposit Current ClinicalTrialDepositCurrent	500000
CY2022Q2	us-gaap	Assets Current AssetsCurrent	13258000
CY2021Q2	us-gaap	Assets Current AssetsCurrent	11793000
CY2022Q2	ktra	Clinical Trial Deposit Non Current ClinicalTrialDepositNonCurrent	2600000
CY2021Q2	ktra	Clinical Trial Deposit Non Current ClinicalTrialDepositNonCurrent	1600000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	90000
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	150000
CY2022Q2	us-gaap	Assets Assets	15948000
CY2021Q2	us-gaap	Assets Assets	13543000
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3269000
CY2021Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2219000
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	721000
CY2021Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	561000
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3990000
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2780000
CY2022Q2	ktra	Milestone Payment Liability MilestonePaymentLiability	163000
CY2021Q2	ktra	Milestone Payment Liability MilestonePaymentLiability	182000
CY2022Q2	us-gaap	Liabilities Liabilities	4153000
CY2021Q2	us-gaap	Liabilities Liabilities	2962000
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	275000000
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	65533000
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32740000
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	66000
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	33000
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	135510000
CY2021Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	106821000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-136356000
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111225000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	21000
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	21000
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15948000
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13543000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15173000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11815000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7509000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9757000
CY2021	ktra	Merger Costs MergerCosts	500000
CY2021	ktra	In Progress Research And Development Expense InProgressResearchAndDevelopmentExpense	16094000
CY2022	us-gaap	Operating Expenses OperatingExpenses	22682000
CY2021	us-gaap	Operating Expenses OperatingExpenses	38166000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	7000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-12000
CY2021	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	94000
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	14000
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-26000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	21000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-132000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-22661000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-38298000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-22661000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-38298000
CY2021	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	3181000
CY2022	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	8000
CY2021	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	8000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25131000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-41504000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.52
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.60
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48702000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25886000
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	263000
CY2021	ktra	Adgero Merger Value AdgeroMergerValue	16725000
CY2021	ktra	Issuance Of Series C Preferred Stock IssuanceOfSeriesCPreferredStock	25028000
CY2021	ktra	Series C Preferred Stock Issue Costs SeriesCPreferredStockIssueCosts	-3455000
CY2021	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	569000
CY2021	ktra	Exercise Of Warrants For Cash ExerciseOfWarrantsForCash	4404000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	77000
CY2021	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-103000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20392000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18860000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5276000
CY2021	ktra	Series Preferred Stock Dividends SeriesPreferredStockDividends	-8000
CY2021	us-gaap	Profit Loss ProfitLoss	-38298000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	10581000
CY2022	ktra	Issuance Of Shares And Warrants Net Of Issue Cost IssuanceOfSharesAndWarrantsNetOfIssueCost	21526000
CY2022	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	35000
CY2022	ktra	Exercise Of2020 Investor Warrants For Cash ExerciseOf2020InvestorWarrantsForCash	69000
CY2022	ktra	Exercise Of Pre Funded Warrants For Cash ExerciseOfPreFundedWarrantsForCash	5000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2248000
CY2022	ktra	Series Preferred Stock Dividends SeriesPreferredStockDividends	-8000
CY2022	us-gaap	Profit Loss ProfitLoss	-22661000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	11795000
CY2022	us-gaap	Profit Loss ProfitLoss	-22661000
CY2021	us-gaap	Profit Loss ProfitLoss	-38298000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2000
CY2022	us-gaap	Depreciation Depreciation	60000
CY2021	us-gaap	Depreciation Depreciation	30000
CY2021	ktra	In Progress Research And Development Expense InProgressResearchAndDevelopmentExpense	16094000
CY2022	ktra	Gain Loss From Change In Fair Value Of Milestone Liability GainLossFromChangeInFairValueOfMilestoneLiability	19000
CY2021	ktra	Gain Loss From Change In Fair Value Of Milestone Liability GainLossFromChangeInFairValueOfMilestoneLiability	6000
CY2021	us-gaap	Interest Expense InterestExpense	30000
CY2021	ktra	Amortization Of Deferred Loan Costs AmortizationOfDeferredLoanCosts	94000
CY2022	ktra	Increase Decrease In Fair Value Of Warrants Issued For Services IncreaseDecreaseInFairValueOfWarrantsIssuedForServices	35000
CY2021	ktra	Increase Decrease In Fair Value Of Warrants Issued For Services IncreaseDecreaseInFairValueOfWarrantsIssuedForServices	569000
CY2022	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	2248000
CY2021	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	5276000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	722000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	381000
CY2022	ktra	Increase Decrease In Clinical Trial Deposits IncreaseDecreaseInClinicalTrialDeposits	-500000
CY2021	ktra	Increase Decrease In Clinical Trial Deposits IncreaseDecreaseInClinicalTrialDeposits	-2100000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1007000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-67000
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	160000
CY2021	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	969000
CY2021	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	8000
CY2021	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	3000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	964000
CY2022	ktra	Proceeds From Issuance Of Shares And Warrants ProceedsFromIssuanceOfSharesAndWarrants	21569000
CY2021	ktra	Proceeds From Issuance Of Shares And Warrants ProceedsFromIssuanceOfSharesAndWarrants	21598000
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	74000
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4404000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	77000
CY2021	us-gaap	Proceeds From Construction Loans Payable ProceedsFromConstructionLoansPayable	500000
CY2021	us-gaap	Repayments Of Debt RepaymentsOfDebt	500000
CY2021	us-gaap	Interest Paid InterestPaid	30000
CY2022	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	8000
CY2021	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	8000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21635000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26041000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1243000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8145000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10537000
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2392000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11780000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10537000
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<div style="text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Nature of operations, corporate history, and going concern and management plans</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Nature of operations</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Kintara Therapeutics, Inc. (the “Company”) is a clinical-stage drug development company with a focus on the development of novel cancer therapies for patients with unmet medical needs. The Company is developing two late-stage, Phase 3-ready therapeutics – VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. In order to accelerate the Company’s development timelines, it leverages existing preclinical and clinical data from a wide range of sources. The Company may seek marketing partnerships in order to potentially offset clinical costs and to generate future royalty revenue from approved indications of its product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Corporate history</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company is a Nevada corporation formed on June 24, 2009, under the name Berry Only, Inc. On January 25, 2013, the Company entered into and closed an exchange agreement (the “Exchange Agreement”), with Del Mar Pharmaceuticals (BC) Ltd. (“Del Mar (BC)”), 0959454 B.C. Ltd. (“Callco”), and 0959456 B.C. Ltd. (“Exchangeco”) and the security holders of Del Mar (BC). Upon completion of the Exchange Agreement, Del Mar (BC) became a wholly-owned subsidiary of the Company (the “Reverse Acquisition”).</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">On June 9, 2020, the Company entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), by and among Adgero Acquisition Corp., the Company’s wholly-owned subsidiary incorporated in the State of Delaware (“Merger Sub”), and Adgero Biopharmaceuticals Holdings, Inc., a Delaware corporation (“Adgero”). On August 19, 2020, upon the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub merged with and into Adgero (the “Merger”), the separate corporate existence of Merger Sub ceased and Adgero continued its existence under Delaware law as the surviving corporation in the Merger and became a direct, wholly-owned subsidiary of the Company. As a result of the Merger, each issued and outstanding share of Adgero common stock, par value $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> per share (the “Adgero Common Stock”) (other than treasury shares held by Adgero), was converted automatically into </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.5740</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> shares (the “Exchange Ratio”) of the Company’s common stock per share of Adgero Common Stock, and cash in lieu of any fractional shares. Also, each outstanding warrant to purchase Adgero Common Stock was converted into a warrant exercisable for that number of shares of the Company’s common stock equal to the product of (x) the aggregate number of shares of Adgero Common Stock for which such warrant was exercisable and (y) the Exchange Ratio.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Following the completion of the Merger, the Company changed its name from DelMar Pharmaceuticals, Inc. to Kintara Therapeutics, Inc. and began trading on The Nasdaq Capital Market LLC under the symbol “KTRA”.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Kintara Therapeutics, Inc. is the parent company of Del Mar (BC), a British Columbia, Canada corporation and Adgero, a Delaware corporation, which are clinical stage companies with a focus on the development of drugs for the treatment of cancer. The Company is also the parent company to Callco and Exchangeco which are British Columbia, Canada corporations. Callco and Exchangeco were formed to facilitate the Reverse Acquisition. In connection with the Adgero merger, the Company also became the parent company of Adgero Biopharmaceuticals, Inc. (“Adgero Bio”), formerly a wholly-owned subsidiary of Adgero.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">References to the Company refer to the Company and its wholly-owned subsidiaries.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Going concern and management plans</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">These consolidated financial statements have been prepared on a going concern basis, which assumes that the Company will continue its operations for the foreseeable future and contemplates the realization of assets and the settlement of liabilities in the normal course of business.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">For the year ended June 30, 2022, the Company reported a loss of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">22,661</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> and a negative cash flow from operations of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">20,392</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">. The Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">136,356</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> and had cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">11,780</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> as of June 30, 2022. The Company is in the clinical stage and has not generated any revenues to-date. The Company does not have the prospect of achieving revenues until such time that its product candidates are commercialized or partnered, which may not ever occur. During the year ended June 30, 2022, the Company completed </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> registered direct financings for aggregate net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">21.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million and on August 2, 2022, the Company entered into a stock purchase agreement which subject to certain limitations, may allow the Company to sell shares of its common stock for a total of up to $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million in gross proceeds. However, potential proceeds under the stock purchase agreement are uncertain as to timing and amount. Even with the proceeds from the </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> registered direct financings and the existence of the stock purchase agreement, the Company will require additional funding to maintain its clinical trials, research and development projects, and for general operations. These circumstances indicate substantial doubt exists about the Company’s ability to continue as a going concern within one year from the date of filing of these consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Consequently, management is pursuing various financing alternatives to fund the Company’s operations so it can continue as a going concern. However, the coronavirus (“COVID-19”) pandemic has created significant economic uncertainty and volatility in the credit and capital markets. Management plans to continue to pursue opportunities to secure the necessary financing through the issue of new equity, debt, and/or the entering into of strategic partnership arrangements but the ultimate impact of the COVID-19 pandemic on the Company’s ability to raise additional capital is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak and any new information which may emerge concerning the severity of the COVID-19 pandemic. The Company may not be able to raise sufficient additional capital and may tailor its drug candidate development programs based on the amount of funding the Company is able to raise in the future. Nevertheless, there is no assurance that these initiatives will be successful.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">These consolidated financial statements do not give effect to any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.</span></p>
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	1.5740
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-22661000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20392000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-136356000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11780000
CY2022	ktra	Number Of Registered Direct Financings Completed NumberOfRegisteredDirectFinancingsCompleted	2
CY2022	ktra	Proceeds From Registered Direct Financing Subsequent ProceedsFromRegisteredDirectFinancingSubsequent	21600000
CY2022	ktra	Number Of Registered Direct Financings Completed NumberOfRegisteredDirectFinancingsCompleted	2
CY2021	ktra	Share Based Compensation Arrangement By Share Based Payment Award Stock Options Granted Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice	1.67
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	2058
CY2021	ktra	Share Based Compensation Arrangement By Share Based Payment Award Stock Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice	1.52
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Use of estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets, and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the fair value of the milestone payment liability, the valuation of equity instruments issued for services, clinical trial accruals, deferred tax valuation allowance and assessment of going concern. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements.</span></p>
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	14
CY2021	ktra	Share Based Compensation Arrangement By Share Based Payment Award Stock Options Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice	1.42
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	3860
CY2021Q2	ktra	Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice	1.60
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3964
CY2022	ktra	Share Based Compensation Arrangement By Share Based Payment Award Stock Options Granted Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice	0.99
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	2388
CY2021	ktra	In Progress Research And Development Expense InProgressResearchAndDevelopmentExpense	16094000
CY2022Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	690000
CY2021Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	665000
CY2022Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	28098000
CY2021Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	22073000
CY2022Q2	ktra	Deferred Tax Liabilities Scientific Research And Development DeferredTaxLiabilitiesScientificResearchAndDevelopment	114000
CY2021Q2	ktra	Deferred Tax Liabilities Scientific Research And Development DeferredTaxLiabilitiesScientificResearchAndDevelopment	110000
CY2022Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	27984000
CY2021Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	21963000
CY2022	us-gaap	Property Plant And Equipment Estimated Useful Lives PropertyPlantAndEquipmentEstimatedUsefulLives	three years
CY2022Q2	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	0
CY2022	ktra	Share Based Compensation Arrangement By Share Based Payment Award Stock Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice	1.56
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	1237
CY2022	ktra	Share Based Compensation Arrangement By Share Based Payment Award Stock Options Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice	1.68
CY2022	ktra	Accruals For Research And Development Expenses And Clinical Trials Policytext Block AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicytextBlock	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Accruals for research and development expenses and clinical trials</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants, and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment terms that do not match the periods over which materials or services are provided under such contracts. The Company’s objective is to reflect the appropriate expenses in its financial statements by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the timing of various aspects of the expenses. The Company determines accrual estimates by taking into account discussion with applicable personnel and outside service providers as to the progress of clinical trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company’s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. For the years ended June 30, 2022, and 2021, there were no material adjustments to the Company’s prior period estimates of accrued expenses for clinical trials.</span></p>
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	27984000
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21963000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2022	us-gaap	Legal Fees LegalFees	1554000
CY2022	us-gaap	Professional Fees ProfessionalFees	500000
CY2022	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	16724000
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	969000
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther	11000
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	175000
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	337000
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	188000
CY2022Q2	ktra	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities In Process Research And Development BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesInProcessResearchAndDevelopment	16094000
CY2022	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	300000
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	240000
CY2022	us-gaap	Payments To Employees PaymentsToEmployees	60000
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4743000
CY2021	ktra	Milestone Payment Liability Addition MilestonePaymentLiabilityAddition	188000
CY2021	ktra	Milestone Payment Liability Change In Fair Value Estimate MilestonePaymentLiabilityChangeInFairValueEstimate	-6000
CY2021Q2	ktra	Milestone Payment Liability MilestonePaymentLiability	182000
CY2022	ktra	Milestone Payment Liability Change In Fair Value Estimate MilestonePaymentLiabilityChangeInFairValueEstimate	-19000
CY2022Q2	ktra	Milestone Payment Liability MilestonePaymentLiability	163000
CY2022Q2	ktra	Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice	4199
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.02
CY2021	ktra	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Intrinsic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedIntrinsicValue	2577000
CY2022	ktra	Share Based Compensation Arrangements By Share Based Payment Award Options Issuance Of2022 April Agent Warrants Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOf2022AprilAgentWarrantsWeightedAverageExercisePrice	0.6625
CY2022	ktra	Patient Enrollment Milestones Payments PatientEnrollmentMilestonesPayments	8163000
CY2021	ktra	Patient Enrollment Milestones Payments PatientEnrollmentMilestonesPayments	5430000
CY2022	ktra	Deposits Payments DepositsPayments	2600000
CY2020Q2	ktra	Property Equipment And Intangibles Assets PropertyEquipmentAndIntangiblesAssets	2000
CY2021	ktra	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment And Intangibles Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAndIntangiblesAssets	32000
CY2021Q2	ktra	Property Equipment And Intangibles Assets PropertyEquipmentAndIntangiblesAssets	150000
CY2022	ktra	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment And Intangibles Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAndIntangiblesAssets	60000
CY2022Q2	ktra	Property Equipment And Intangibles Assets PropertyEquipmentAndIntangiblesAssets	90000
CY2022	us-gaap	Payments For Software PaymentsForSoftware	80000
CY2021	us-gaap	Payments For Software PaymentsForSoftware	80000
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	2000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-8015000
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	721000
CY2021Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	561000
CY2022Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1000
CY2021	ktra	Seriesb Preferred Stock Dividend Shares SeriesbPreferredStockDividendShares	11000
CY2021Q3	ktra	Underwritten Public Offerings Description UnderwrittenPublicOfferingsDescription	the Company closed on the sale of (i) 7,200 shares of its common stock, par value $0.001 per share, (ii) pre-funded warrants (“PFW”) to purchase an aggregate of 4,800 shares of common stock and (iii) common warrants to purchase an aggregate of 12,000 shares of common stock (“2022 Investor Warrants”) in the Company’s registered direct offering (the “September Offering”). Each share of common stock, or PFW as applicable, was sold together with a 2022 Investor Warrant to purchase one share of common stock at a combined effective price of $1.25 per share of common stock and accompanying 2022 Investor Warrant. The 2022 Investor Warrants have been valued at $7,023 and have been treated as equity. They have been valued using a Black-Scholes valuation with a risk-free rate of 0.55%, a contractual term of 3.5 years, a volatility of 116.7%, and a dividend rate of 0%.
CY2022Q2	ktra	Underwritten Public Offerings Description UnderwrittenPublicOfferingsDescription	the Company closed on the sale of 16,266 shares of its common stock, par value $0.001 per share, and common warrants to purchase an aggregate of 16,266 shares of common stock (“2022 April Investor Warrants”) in the Company’s registered direct offering (the “April Offering”). Each share of common stock was sold together with a 2022 April Investor Warrant to purchase one share of common stock at a combined effective price of $0.53 per share of common stock and accompanying 2022 April Investor Warrant. The 2022 April Investor Warrants have been valued at $3,898 and have been treated as equity. They have been valued using a Black-Scholes valuation with a risk-free rate of 0.54%, a contractual term of 5 years, a volatility of 109.4%, and a dividend rate of 0%.
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8810000
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4611000
CY2022	ktra	Income Tax Reconciliation Permanent Differences IncomeTaxReconciliationPermanentDifferences	802000
CY2021	ktra	Income Tax Reconciliation Permanent Differences IncomeTaxReconciliationPermanentDifferences	4506000
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-345000
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-551000
CY2022	ktra	Income Tax Reconciliation Effect Of Foreign Exchange Rates IncomeTaxReconciliationEffectOfForeignExchangeRates	445000
CY2021	ktra	Income Tax Reconciliation Effect Of Foreign Exchange Rates IncomeTaxReconciliationEffectOfForeignExchangeRates	-954000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2248000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5276000
CY2020Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	858
CY2020Q2	ktra	Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice	0.98
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5074
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	25541000
CY2021Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20148000
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	635000
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	155000
CY2022Q2	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	18000
CY2021Q2	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	18000
CY2022Q2	ktra	Deferred Tax Assets Financing Cost DeferredTaxAssetsFinancingCost	326000
CY2021Q2	ktra	Deferred Tax Assets Financing Cost DeferredTaxAssetsFinancingCost	326000
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	85000
CY2022Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	803000
CY2021Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	761000
CY2021	ktra	Income Tax Reconciliation Non Capital Losses Acquired IncomeTaxReconciliationNonCapitalLossesAcquired	-4114000
CY2022	ktra	Income Tax Reconciliation Nondeductible Expense Benefit Research And Development IncomeTaxReconciliationNondeductibleExpenseBenefitResearchAndDevelopment	-44000
CY2021	ktra	Income Tax Reconciliation Nondeductible Expense Benefit Research And Development IncomeTaxReconciliationNondeductibleExpenseBenefitResearchAndDevelopment	97000
CY2022	ktra	Income Tax Reconciliation Adjustment To Prior Year S Provision Versus Statutory Tax Returns IncomeTaxReconciliationAdjustmentToPriorYearSProvisionVersusStatutoryTaxReturns	-2332000
CY2021	ktra	Income Tax Reconciliation Adjustment To Prior Year S Provision Versus Statutory Tax Returns IncomeTaxReconciliationAdjustmentToPriorYearSProvisionVersusStatutoryTaxReturns	228000
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	196000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6021000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	8803000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	29700000
CY2022	ktra	Percentage Of Taxable Income Limitation On No Ls PercentageOfTaxableIncomeLimitationOnNOLs	0.80
CY2022	us-gaap	Tax Credit Carryforward Description TaxCreditCarryforwardDescription	expire between 2031 and 2041
CY2022	ktra	Minimum Cumulative Percentage Of Change In Ownership As Condition To Offset Taxable Income Or Tax MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax	0.50
CY2022	ktra	Cumulative Change In Ownership Period CumulativeChangeInOwnershipPeriod	P3Y
CY2022	ktra	Manufacturing And Clinical Study Management Related Cost ManufacturingAndClinicalStudyManagementRelatedCost	14880000
CY2022	ktra	Clinical Development Research Deposits ClinicalDevelopmentResearchDeposits	3269000
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	41400
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	40000
CY2021	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	3181000
CY2022	ktra	Non Cash Issue Costs NonCashIssueCosts	683000
CY2021	ktra	Non Cash Issue Costs NonCashIssueCosts	3287000
CY2022	ktra	Issue Costs In Accounts Payable IssueCostsInAccountsPayable	43000
CY2021	ktra	Conversion Of Series B Preferred Stock Shares To Common Stock ConversionOfSeriesBPreferredStockSharesToCommonStock	4525000
CY2022	ktra	Conversion Of Series C Preferred Stock To Common Stock ConversionOfSeriesCPreferredStockToCommonStock	2377000
CY2021	ktra	Conversion Of Series C Preferred Stock To Common Stock ConversionOfSeriesCPreferredStockToCommonStock	3713000
CY2022	us-gaap	Concentration Risk Credit Risk Financial Instrument Maximum Exposure ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure	19000
CY2022	ktra	Concentration Risk Credit Risk Uninsured Amount Of Cash ConcentrationRiskCreditRiskUninsuredAmountOfCash	11185000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11780000
CY2022Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	595000
CY2022Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	11185000

Files In Submission

Name	View Source	Status
0000950170-22-018865-index-headers.html	Edgar Link	pending
0000950170-22-018865-index.html	Edgar Link	pending
0000950170-22-018865.txt	Edgar Link	pending
0000950170-22-018865-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img138742198_0.jpg	Edgar Link	pending
img138742198_1.jpg	Edgar Link	pending
img138742198_2.jpg	Edgar Link	pending
img138742198_3.jpg	Edgar Link	pending
img138742198_4.jpg	Edgar Link	pending
ktra-20220630.htm	Edgar Link	pending
ktra-20220630.xsd	Edgar Link	pending
ktra-ex10_33.htm	Edgar Link	pending
ktra-ex21_1.htm	Edgar Link	pending
ktra-ex23_1.htm	Edgar Link	pending
ktra-ex31_1.htm	Edgar Link	pending
ktra-ex31_2.htm	Edgar Link	pending
ktra-ex32_1.htm	Edgar Link	pending
ktra-ex32_2.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ktra-20220630_cal.xml	Edgar Link	unprocessable
ktra-20220630_def.xml	Edgar Link	unprocessable
ktra-20220630_lab.xml	Edgar Link	unprocessable
ktra-20220630_pre.xml	Edgar Link	unprocessable
ktra-20220630_htm.xml	Edgar Link	completed
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HURA
DELMAR PHARMACEUTICALS, INC. Stock $hura

2022 Q3 Form 10-K Financial Statement

#000095017022018865 Filed on September 27, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HURA DELMAR PHARMACEUTICALS, INC. Stock $hura

2022 Q3 Form 10-K Financial Statement

#000095017022018865 Filed on September 27, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HURA
DELMAR PHARMACEUTICALS, INC. Stock $hura